NRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program
NRx Pharmaceuticals Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality
NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications
NRx Pharmaceuticals Announces Appointment of Glenn Tyson as the Company's first Chief Commercial Officer
NRx Pharmaceuticals Announces FDA Labeling Alignment for NRx's Preservative-Free Ketamine Application
NRx Pharmaceuticals Announces FDA Labeling Alignment for NRx's Preservative-Free Ketamine Application
Hope Therapeutics, an NRx Pharmaceuticals Subsidiary , Announces Strategic Partnership with Emobot to Integrate its AI-Powered "Depression Thermometer" Across its Interventional Psychiatry Network
NRx Pharmaceuticals Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress
NRx Pharmaceuticals, Inc. to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026
NRx Pharmaceuticals Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx's Preservative-Free Ketamine Application
NRx Pharmaceuticals Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 Following Type C FDA Meeting
HOPE Therapeutics, an NRx Subsidiary Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD
NRx Pharmaceuticals Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 Following Type C FDA Meeting
Gold Runner Exploration Completes 2026 Option Payment For Falcon Property Near Elko Nevada And Provides Update On Exploration Plans
